Loading…
Back To Schedule
Wednesday, June 27 • 4:00pm - 5:15pm
#391: How to De-Risk Alliances for Success

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Session
Level: Intermediate
CE: CME 1.25; IACET 1.25; PDU 1.25 PMI 2166-000230; RN 1.25

A significant number of partnerships fail. By going beyond standard practices to de-risk for success pre- and post-partnering, firms can avoid reduced revenue, elevated costs and brand damage due to failed alliances and partnerships. This session will include how to make a go or no go decision plus engagement on an ongoing basis, including periodic checks on milestones and soft targets such as engagement level, communication effectiveness, and others.

Learning Objectives

State at least three common causes of partnership failure; Explain hard and soft (such as cultural) due diligence; Describe at least three activities or strategies a sponsor or vendor may use to de-risk a partnership/alliance.

Chair

Candice Hughes

Speaker

De-Risking Alliances, The Sponsor Perspective: Transforming Expectations and Implementing Innovations for Joint Oversight
Jessica Dero, PMP

The Vendor Perspective on De-Risking Partnerships for Shared Success
Candice Hughes

Sponsor Perspective
Alison Schecter, MD, FACC


Speakers
avatar for Jessica Dero

Jessica Dero

Vendor Strategy, Janssen Pharmaceutical Companies of Johnson & Johnson
Jessica holds a Bachelor’s of Science degree in Bioengineering from Lehigh University and is a certified Project Management Professional. Jessica works for Janssen Inc., within Bioresearch Quality and Compliance as Associate Director of Vendor Strategy. Jessica develops and manages... Read More →
avatar for Candice Hughes

Candice Hughes

CEO/Founder, Hughes BioPharma Advisers LLC
Candice M Hughes, PhD, MBA, is a strategy and management consultant helping with Alliance Management for biopharma firms via Hughes BioPharma Advisers. She is also a serial entrepreneur who founded a digital health startup. She has worked with over a third of the top 25 global pharma... Read More →
avatar for Alison Schecter

Alison Schecter

Global Project Head, Rare Disease, Sanofi
Dr. Schecter is GPH for Rare Disease (RD) Development at Sanofi. She is responsible for defining the strategic focus of RD Dev. in collaboration with RD Commercial. She works with EI and BD to review and make decisions about ext. opportunities. Alison leads the ASMD (formerly as Niemann-Pick... Read More →

Wednesday June 27, 2018 4:00pm - 5:15pm EDT
Room 209 Boston Convention and Exhibition Center 415 Summer Street, Boston, MA 02210 USA
  07: ProjMgt-StrategicPlanning, Session